Table 1.
Patient and tumor characteristics.
| Variable | Overall (n = 79) | Chemotherapy (n = 46) | Endocrine therapy (n = 33) | P-Value |
|---|---|---|---|---|
| Age at diagnosis (years, SD) | 56.5 (9.7) | 54.1 (8.3) | 59.9 (10.5) | 0.159 |
| Receptor subtype (n = 75) | 0.022 | |||
| ER+/PR+/HER2− | 39 (52.0) | 21 (46.7) | 18 (60.0) | |
| ER+/PR−/HER2− | 24 (32.0) | 12 (26.7) | 12 (40.0) | |
| Triple negative | 1 (1.3) | 1 (2.2) | 0 (0.0) | |
| HER2+ | 11 (14.7) | 11 (24.4) | 0 (0.0) | |
| ILC Grade | 0.140 | |||
| 1 | 23 (29.1) | 11 (23.9) | 12 (36.4) | |
| 2 | 52 (65.8) | 31 (67.4) | 21 (63.6) | |
| 3 | 4 (5.1) | 4 (8.7) | 0 (0.0) | |
| ILC Stage | 0.001 | |||
| 1 | 33 (41.8) | 13 (28.3) | 20 (60.6) | |
| 2 | 31 (39.2) | 26 (56.5) | 5 (15.2) | |
| 3 | 15 (19.0) | 7 (15.2) | 8 (24.2) | |
| Lymphovascular Invasion | 7 (8.9) | 5 (10.9) | 2 (6.1) | 0.458 |
| Radiation (n = 77) | 52 (67.5) | 32 (69.6) | 20 (64.5) | 0.643 |
| Treatment type (n = 77) | 0.070 | |||
| Lumpectomy without radiation | 7 (9.1) | 3 (6.5) | 4 (12.9) | |
| Lumpectomy with radiation | 25 (32.5) | 11 (23.9) | 14 (45.2) | |
| Mastectomy | 18 (23.4) | 11 (23.9) | 7 (22.6) | |
| Mastectomy with radiation | 27 (35.1) | 21 (45.7) | 6 (19.4) | |
| Axillary surgery | 0.023 | |||
| Sentinel lymph node biopsy | 36 (45.6) | 16 (34.8) | 20 (60.6) | |
| Axillary dissection | 43 (54.4) | 30 (65.2) | 13 (39.4) | |
| Clinical node status | <0.001 | |||
| Positive | 30 (38.0) | 22 (47.8) | 8 (24.2) | |
| Negative | 49 (62.0) | 24 (52.2) | 25 (75.8) | |
| Pathologically node positive at surgery | 44 (55.7) | 29 (63.0) | 15 (45.5) | 0.067 |
| 1–3 Positive nodes | 25 (31.7) | 20 (43.5) | 5 (15.2) | |
| 4–9 Positive nodes | 11 (13.9) | 5 (10.9) | 6 (18.2) | |
| 10 or more positive nodes | 8 (10.1) | 4 (8.7) | 4 (12.1) | |
| Size of cancer in positive nodes, cm (mean, SD) (n = 44) | 0.87 (0.67) | 0.79 (0.56) | 1.02 (0.84) | 0.083 |
| Patients with positive nodes ≥ cm (n = 44) | 16 (36.4) | 11 (37.9) | 5 (33.3) | 0.764 |